Approved for use through 07/31/2006. OMB 0651-0031
Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

				Complete if Known		
Substitute fo	Substitute for form 1449/PTO INFORMATION DISCLOSURE			Application Number	09/990,611	
INFORM				Filing Date	November 21, 2001	
STATEM	STATEMENT BY APPLICANT (Use as many sheets as necessary)		First Named Inventor	Lorraine Faxon Meisner		
(Use as			Art Unit	1616		
			Examiner Name	Frank I. Choi		
Sheet	1	Of	6	Attorney Docket Number	36091-701.302	

		U.S. P.	ATENT DOC	UMENTS	
Examiner Cite Initials* No. 1		Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	2001/0041193 A1	11-15-2001	Meisner	
	2.	2002/0037314 A1	03-28-2002	Meisner	
	3.	2002/0164386 A1	11-07-2002	Meisner	
	4.	2005/0003023 A1	01-06-2005	Meisner	
	5.	2006/0165819 A1	07-27-2006	Meisner	
	6.	2008/0125395 A1	05-29-2008	Meisner	
	7.	2,400,171	05-14-1946	Ruskin et al.	
	8.	2,442,461	06-01-1948	Karrer	
	9.	3,857,970	12-31-1974	Tsumura, et al.	
	10.	3,886,265	05-27-1975	Evers et al.	
	11.	4,229,430	10-21-1980	Fahim et al.	
	12.	4,294,852	10-13-1981	Wildnauer et al.	
	13.	4,367,157	01-04-1983	Sherman	
	14.	4,515,771	05-07-1985	Fine	
	15.	4,590,067	05-20-1986	Meisner	
	16.	4,647,453	03-03-1987	Meisner	
	17.	4,711,780	12-08-1987	Fahim	
	18.	4,722,936	02-02-1988	Jacob	
	19.	4,772,591	09-20-1988	Meisner	
	20.	4,818,521	04-04-1989	Tamabuchi	
	21.	5,700,451	12-23-1997	Yue, et al.	
	22.	5,703,122	12-30-1997	Duffy	
	23.	5,736,567	04-07-1998	Cantin et al.	

Examiner			Date		
Signature			Considered		
				citation if not in conformance and not considered. I	
of this form with nex	ct communication to applicant.	Applicant's unsome citation designation number	r (ontional). 2See Kinds Co.	des of LISPTO Patent Documents at www.usnto.gov.	or MPEP

of the form with first communication to applicate. "Applicant's respect clinical designation immber (opticant). "See Kailf Cooks of USFOTO Paint December as were proposed to the real number of the paint december." Kailf of Sciented the Represents were proposed to the real number of the paint december. "Kailf of Sciented the Represents opticals and anisotated at the december on the WIDT United PST (of possible, PST and Sciented Scienter). The Cooks of USFOTO In the USFOTO In the USFOTO In the Cooks of USFOTO In the USFO

clock mids. here if English language. Translation is stacked.

The collection of indextunities in regular by 27 CR 1.97 and 1.98. The information is required to obtain or ration a benefit by the public velicit is to file (and by the USFTO to process) an application. Confidentially in governed by 8 USC 1.22 and 7 CR 1.14. This collection in feature to take 2 hours to complete, including gathering, preparing, and substituting the complete of positions from the USFTO. Time will very depending upon the inforbal case. Any openment on the accord of time year require to complete in factor made and complete in factor and the complete in factor and also appeared to the complete in factor and also and the complete in factor and also appeared to the complete in factor

Approved for use through 07/31/2006. OMB 0651-0031 Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

				Complete if Known		
Substitute fo	r form 1449.	/PTO		Application Number	09/990,611	
INFORM	IN ORMITTO NDISCEOSCRE			Filing Date	November 21, 2001	
STATEM				First Named Inventor	Lorraine Faxon Meisner	
(Use as	many sheets	as ne	essary)	Art Unit	1616	
				Examiner Name	Frank I. Choi	
Sheet	2	Of	6	Attorney Docket Number	36091-701.302	

	U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	24.	5,750,123	05-12-1998	Znaiden et al.			
	25.	5,972,993	10-26-1999	Ptchelintsev			
	26.	6,440,465	08-27-2002	Meisner			

	FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ – Number ⁴ – Kind Code ³ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶	
	27.	EP 0273202	06-21-1995	Van Scott			
	28.	EP 0771557	08-18-1999	L'Oreal			
	29.	JP 61078715 (English language abstract)	04-22-1986	Shiseido Co. Ltd.		AE	
	30.	WO 98/23152	06-04-1998	Perricone			
	31.	WO 00/56327	09-28-2000	Bioderm, Inc.			
	32.	WO 01/83031	11-08-2001	Bioderm, Inc.			

		NON PATENT LITERATURE DOCUMENTS
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	33.	BANDELIN & TUSCHHOFF, "The Stability of Ascorbic Acid in Various Liquid Media", J. Am. Pharmacol. Assoc. 44(4):241-244 (1955)
	34.	BAUERNFEIND, "Ascorbic Acid Technology" in ASCORBIC ACID: CHEMISTRY, METABOLISM, AND USES, 417-29 (Seib & Tolbert, eds., American Chemical Society 1982)
	35.	BEKESI et al., "Inhibitory Effect of D-Glucosamine and Other Sugar Analogs on the Viability and Transplantability of Ascites Tumor Cells", Cancer Research 29:353-359 (1969)

Examiner		Date	
Signature		Considered	
*EXAMINER:	Initial if reference considered, whether or not citation is in conformance with MPEP 609	Draw line through	Include copy

of this form with next communication to application. As some as no accusate man on contenueme with MPT 60°. Does the though existing it not in conformance and no con

cases inter, served a friging singuage, in trabulous a situation. The collection of information is required by \$7 CPR 197 and 198. The information is required by the collection of information is required by \$7 CPR 197 and 198. The information is required by a complex considerable programmed by \$7 CPR 197 and 197 CPR 114. This collection is estimated to take 2 hours to complete, including guidening preparing, and arbenting the excellent programmed by \$7 CPR 197 and 197 CPR 114. This collection is estimated to take 2 hours to complete, including guidening preparing, and arbenting the excellent programmed by \$7 CPR 197 CPR 19

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

				Complete if Known		
Substitute for form 1449/PTO				Application Number	09/990,611	
INFORM	INFORMATION DISCLOSURE			Filing Date	November 21, 2001	
STATEM	STATEMENT BY APPLICANT		First Named Inventor	Lorraine Faxon Meisner		
(Use as	many sheets	as ne	cessary)	Art Unit	1616	
			Examiner Name	Frank I. Choi		
Sheet	3	Of	6	Attorney Docket Number	36091-701.302	

		NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(5), volume-issue number(s), publisher, city andror country where published.			
	36.	BLACK, "Potential Involvement of Free Radical Reactions in Ultraviolet Light-Mediated Cutaneous Damage", <i>Photochemistry and Photobiology</i> 46:213-221 (1987)			
	37.	BORNE & PEDEN "Antiinflammatory Activity of Para-Substituted N-Benzenesulfonyl Derivatives of Amino Acids", <i>J. Med. Chem.</i> 15(12):1325-1326 (1972)			
	38.	COOKE & MOXON, "The Detection and Measurement of Vitamin C", in VITAMIN C (ASCORBIC ACID), 167-168, 170-171 (Counsell & Hornig, eds., Applied Science Publishers 1981)			
	39.	ENGLARD & SEIFTER, "The Biochemical Functions of Ascorbic Acid", Ann. Rev. Nutri. 6:365-406 (1986)			
40.		GUALANO et al., "Anti-inflammatory Activity of S-Adenosyl-L-Methionine: Interference with the Eicosanoid System", <i>Pharmacology Res. Commun.</i> 15(7):683-695 (1983)			
	41.	HAJRATWALA, "Stability of Ascorbic Acid", S.T.P. Pharma, 1(4):281-286 (1985)			
	42.	HALL et al., "Anti-Inflammatory Activity of Diazomethyl Ketone and Chloromethyl Ketone Analogs Prepared from N-Tosyl Amino Acids", J. Pharm. Sci. 69(12):1451-1452 (1980)			
	43.	HORNIG & MOSER, "The Safety of High Vitamin C Intakes in Man", in VITAMIN C (ASCORBIC ACID) 225-226 (Counsell & Hornig, eds., Applied Science Publishers 1981)			
		IMAI et al., "The Antiscorbutic Activity of L-Ascorbic Acid Phosphate Given Orally and Percutaneously in Guinea Pigs", <i>Jap. J. Pharmacol.</i> 317-324 (1967)			
	45.	JAIN & KHANNA, "Evaluation of Anti-inflammatory and Analgesic Properties of L-Glutamine", Agents and Actions 11(3):243-248 (1981)			
	46.	KAHN et al., "Ultraviolet Light Protection by Several New Compounds", Arch Dermatol. 109 510-517 (1974)			

Examiner		Date	
Signature		Considered	
	nitial if reference considered, whether or not citation is in conformance with MPEP 609		
of this form with no	et communication to applicant : Applicant le unione citation decimation number (ortion	al) 2San Kinde Cod	ar of HSPTO Patent Documents at unusur nexts you or MPED

of this form with next communication to applicant. *Applicant's image citation designation number (optional). *See Kinds Code of USPTO Patent Documents at www uspto, go or of MFDF 901.01 *Times of Office that issuand the document, by the insolutes too (WFDO Standard ST.). *See Jajaance patent document, the inflation of the pare of the patent patent of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WFDO Standard ST.16 if possible. *Applicant is to place a chock much ber at Effection Issuages.*

clock and, here if English language Translation is statistical.

The collection of information is required by CTA [19] and 196. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially as generated by St. 1962. CTA [19] and 1968. The information is required to obtain the above to complete, including galaxiering preparing, and arbenting the confidence of the confidenc

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

				Complete if Known		
Substitute for form 1449/PTO INFORMATION DISCLOSURE				Application Number	09/990,611	
			LOSURE	Filing Date	November 21, 2001	
STATEM	STATEMENT BY APPLICANT		First Named Inventor	Lorraine Faxon Meisner		
(Use as	many sheets	as ne	cessary)	Art Unit	1616	
				Examiner Name	Frank I. Choi	
Sheet	4	Of	6	Attorney Docket Number	36091-701.302	

		NON PATENT LITERATURE DOCUMENTS
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	47.	KAPLAN et al., "A New Stabilized Ascorbic Acid Solution: Percutaneous Absorption and Effect on Relative Collagen Synthsies", <i>J. Cutaneous Aging & Cosmetic Derm.</i> 1(2):115-121 (1988/89)
	48.	KASSEM et al., "Studies on the Stability of Injectable L-Ascorbic Acid Solutions: III. Effect of Metal-complexing Agents", <i>Pharma. Acta Helvetiae</i> 47:89-97 (1972)
	49.	KASSEM et al., "Studies on the Stability of Injectable L-Ascorbic Acid Solutions: I. Effect of pH, Solvent, Light and Container", <i>Pharmaceutica Acta Helvetiae</i> 44:611-623 (1969)
	50.	KOLATA, "Is Tyrosine the Key to Growth Control?" Science 219:377-378 (1983)
	51.	KUNERT & TAPPEL, "The Effect of Vitamin C on in vivo Lipid Peroxidation in Guinea Pigs as Measured by Pentane and Ethane Production", Lipids 18(4):271-273 (1983)
52. Immunotropic and Anti-inflammatory Activity", Arch. Im (1979) LASZLO et al., "Effects of Glucose Analogues (2-Deoxy-		KWAPISZEWSKI et al., "Synthesis of L-Cysteine and S-Methyl-L-Cysteine Derivatives of Immunotropic and Anti-inflammatory Activity", Arch. Immunol. Et Ther. Exp. 27(6):729-731 (1979)
		LASZLO et al., "Effects of Glucose Analogues (2-Deoxy-D-glucose, 2-Deoxy-D-galactose) on Experimental Tumors", <i>Journal of the National Cancer Institute</i> 24(2):267-278 (1960)
	54.	LIEN et al., "Topical Use of Ascorbic Acid in the Management of Pressure Sore", <i>J. Formosan Med. Assoc.</i> , 75:243-250 (1976)
	55.	LITWIN, "Growth of Human Diploid Fibroblasts in Media with Different Amino Acid Composition", J. Cell Science 14:671-680 (1974)
	56.	NOBILE et al., VITAMIN C: THE MYSTERIOUS REDOX-SYSTEM A TRIGGER OF LIFE?, 23-24 (MIP Press Ltd., Boston, MA 1981)
	57.	PINNELL & MURAD, "Vitamin C and Collagen Metabolism," in CUTANEOUS AGING, 275-292 (Kligman & Tukase, eds. Univ. of Tolyo Press 1988)

Examiner		Date		
Signature		Considered		
*EXAMINER:	Initial if reference considered, whether or not citation is in conformance with MPEP 609	Draw line through	itation if not in conformance and not considered	Include o

of this form with next commissionate to applicate. *Applicate* susages existed origination number (system). *See Kind Codes of USFOP Pieter Document as we way upon or NPET* [90] of "Third Codes in the instead the document, by the two-left code (with OSManded 15T). *See Kind Codes of USFOP Pieter Document as we way upon or NPET* [90] of "Third Codes in the instead the document, by the two-left code (with OSManded 15T). *See Kind Codes of USFOP Pieter Document as we upon part of the Pieter of the Pieter

check met been of English language. Translation is stateded.

This collection of foreignization is required by 50 CER 187 and 158. The information is required by ochain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by \$8 USC 122 and \$7 CER 114. This collection is foreignized positions from the USPTO may be a substituting the complete applications from the USPTO may will vary depending upon the inforbed case. Any comments to the assured of time year require to complete in Section and we supplements and the assured of time year require to complete in Section and the supplements and the assured of time year require to complete in Section and Section 2008. The supplements are the assured of time year require to complete in Section and Section 2008. The Section 2008 of the Section 2 If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

				Complete if Known		
Substitute fo	or form 1449	/PTO		Application Number	09/990,611	
INFORMATION DISCLOSURE				Filing Date	November 21, 2001	
STATEMENT BY APPLICANT (Use as many sheets as necessary)			LICANT	First Named Inventor	Lorraine Faxon Meisner	
			cessary)	Art Unit	1616	
				Examiner Name	Frank I. Choi	
Sheet	5	Of	6	Attorney Docket Number	36091-701.302	

		NON PATENT LITERATURE DOCUMENTS
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	58.	SETNIKAR et al., "Antireactive Properties of Glucosamine Sulfate," Arzneimittel Forschung Drug Research 41:157-161 (1991)
	59.	SMART et al., "Inhibition of 12-O-Tetradecanoylphorbol-13-acetate Induction of Ornithine Decarboxylase Activity, DNA Synthesis, and Tumor Promotion in Mouse Skin by Ascorbic Acid and Ascorbyl Palmitate", Cancer Res. 47:6633-6638 (1987)
	60.	TAPADINHAS et al., "Oral Glucosamine Sulphate in the Management of Arthrosis: Report or a Multi-centre Open Investigation in Portugal", <i>Pharmatherapeutica</i> 3(3):157-168 (1982)
	61.	THE MERCK INDEX: AN ENCYCLOPEDIA OF CHEMICALS AND DRUGS, 110-111 (#845-858) (Windholz, et al. eds., Merck and Co., 9th ed. 1976)
	62.	THOMAS et al., "Anti-inflammatory Activity of Esters of Phenylglycine", Communications J. Pharm. Pharmacol. 26:151-152 (1974)
	63.	WEST & TODD, TEXTBOOK OF BIOCHEMISTRY 795 (The MacMillan Company, New York 1951)
	64.	Office Action mailed February 29, 2008 in connection with U.S. Patent Application No. 09/997,663, assigned to Bioderm, Inc., under examination by Examiner Choi at the USPTO
	65.	Claims pending on February 29, 2008 in connection with U.S. Patent Application No. 09/997,663, assigned to Bioderm, Inc., under examination by Examiner Choi at the USPTO
	66.	Office Action mailed June 13, 2006 in connection with U.S. Patent Application No. 10/614,768, assigned to Bioderm, Inc., now abandoned
	67.	Claims pending on June 13, 2006 in connection with U.S. Patent Application No. 10/614,768, assigned to Bioderm, Inc., now abandoned
	68.	Office Action mailed November 5, 2007 in connection with U.S. Patent Application No. 11/389,384, assigned to Bioderm, Inc., now abandoned

Examiner		Date		ī
Signature		Considered		
*EXAMINER: I	nitial if reference considered, whether or not citation is in conformance with MPEP 609	Draw line through o	itation if not in conformance and not considered.	n

include copy of this form with next commissionate to applicate. *Applicate* susages existed origination number (system). *See Kind Codes of USFOP Pieter Document as we way upon or NPET* [90] of "Thirt Coffice in the instead the document, by the two-left cross (Will No Standard 15T). *See Applicate parts of Comment, the indicates of their cases of the right of the Emperor must preced the senial number of the partner document. *Kind of consument by the appropriate symbols as indicated on the document worker WITO Standard 15T. *Defended 15T. for the proper must preced the senial number of the partner document. *Kind of consument by the appropriate symbols as indicated on the document worker WITO Standard 15T. for the partner document is not the partner of the pa

clock met been of English language. Translation is stateded.

This collection of foreignization is required by 50 CER 187 and 158. The information is required by or obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by \$8 USC 122 and \$7 CER 114. This collection is foreignized positions from the USPTO or process an application. Confidentially is governed by \$8 USC 122 and \$7 CER 114. This collection is estimated to take 2 boars to complete, including gathering, preparing, and substitting the complete displacions from the USPTO Time will study application give the individual case. Any comments to the assured of time year require to complete in foreign and complete If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08 (07/05)

Approved for use through 07/31/2006. OMB 0651-0031

Approve the use inauguration in STANDARD COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

				Complete if Known		
Substitute fo	r form 1449.	/PTO		Application Number	09/990,611	
INFORMATION DISCLOSURE				Filing Date	November 21, 2001	
STATEMENT BY APPLICANT (Use as many sheets as necessary)			LICANT	First Named Inventor	Lorraine Faxon Meisner	
			essary)	Art Unit	1616	
				Examiner Name	Frank I. Choi	
Sheet	6	Of	6	Attorney Docket Number	36091-701.302	

	NON PATENT LITERATURE DOCUMENTS						
Examiner Cite (book, magazine, journal, serial, symposium, catalog, etc.), date		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
	69.	Claims pending on November 5, 2007 in connection with U.S. Patent Application No. 11/389,384, assigned to Bioderm, Inc., now abandoned					
	70.	Office Action mailed November 2, 2007 in connection with U.S. Patent Application No. 10/185,388, assigned to Bioderm, Inc., under examination by Examiner Flood at the USPTO					
	71.	Claims pending on November 2, 2007 in connection with U.S. Patent Application No. 10/185,388, assigned to Bioderm, Inc., under examination by Examiner Flood at the USPTO					

Examiner		Date	
Signature		Considered	
*EXAMINER: Is	nitial if reference considered, whether or not citation is in conformance with MPEP 609	Draw line through o	itation if not in conformance and not considered. Include copy

of this form with next communication to applicate. "Applicate 'sunger clinical length and profession and the form with next communication to applicate." Applicate 'sunger clinical length and profession. "See Kinds Codes of USEVID Patent Decements as we want good now NEWE's 100,000 (a "Enter Office in the mouth of the content, by the two-before code (PMO) Standard \$8.73. "In "Equipmose parter discoverage, the indication of the pares of the ringer see of the ringer see of the ringer of the Patent per content per code of the result in the patent document. "Kind of Scotners by the appropriate symbols as indicated on the document usedor WIPO Standard \$871. In "If possible." "Applicant is to place a dock market to "Efficient bis capacity" in a standard.

check met here if English language Translation in statisched.

The Collection of Endermain in required by CER 197 and 198. The information in required to obtain or retain a benefit by the public which is to file (and by the USFTO to process) an application. Confidentially in government by SE USE 122 and 37 CFR 14. This collection of Endermain to English Collection and English Confidence and the Collection of English Confidence and the Collection of English Collection and Confidence and Collection and Confidence and Collection and Collection